Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans (Q48259726)

10 February 2018

title

Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans (English)

1 reference

10 February 2018

1 reference

4

Gjedde A

1 reference

10 February 2018

1

Cumming P

1 reference

10 February 2018

author name string

Léger GC

series ordinal

2

1 reference

10 February 2018

Kuwabara H

series ordinal

3

1 reference

10 February 2018

publication date

1 July 1993

1 reference

10 February 2018

Journal of Cerebral Blood Flow & Metabolism

published in

1 reference

10 February 2018

volume

13

1 reference

10 February 2018

issue

4

1 reference

10 February 2018

page(s)

668-675

1 reference

10 February 2018

Determination of plasma [18F]-6-fluorodopa during positron emission tomography: elimination and metabolism in carbidopa treated subjects

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

The metabolism of [18F]6-fluoro-L-3,4-dihydroxyphenylalanine in the hooded rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Kinetics of in vitro decarboxylation and the in vivo metabolism of 2-18F- and 6-18F-fluorodopa in the hooded rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Distribution and kinetics of 3-O-methyl-6-[18F]fluoro-L-dopa in the rhesus monkey brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Dopamine visualized in the basal ganglia of living man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Dopa decarboxylase activity of the living human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Parkinsonism: onset, progression, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Kinetics and modeling of L-6-[18F]fluoro-dopa in human positron emission tomographic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

18F‐6‐Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR‐462)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

6-[18F]fluoro-L-dopa metabolism in MPTP-treated monkeys: assessment of tracer methodologies for positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Blood-brain transfer and metabolism of 6-[18F]fluoro-L-dopa in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Dopamine 3-O-sulphate, an end product of L-dopa metabolism in Parkinson patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

Peripheral aromaticl-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism ofl-2-14C-dopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

7 January 2021

Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

7 January 2021

Metabolism of 3,4-dihydroxyphenylalanine (l-DOPA) in human subjects

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

7 January 2021

Episodic symptoms mistaken for seizures in the neurologically impaired child

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

7 January 2021

The effects of carbidopa on the metabolism of 6-[18F]fluoro-L-dopa in rats, monkeys and humans

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

7 January 2021

L-dopa decarboxylation in chronically treated patients

1 reference

https://api.crossref.org/works/10.1038%2FJCBFM.1993.85

7 January 2021

Identifiers

DOI

10.1038/JCBFM.1993.85

1 reference

10 February 2018

1 reference

10 February 2018